This study is a randomized, open-label Phase 2 study to compare the efficacy and safety of IBI363 Combined with Chemotherapy or Pembrolizumab Combined with Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer.
Males and Females, age ≥18 years and ≤75 years;
Stage IB, II, IIIA or IIIB (N2) NSCLC (per AJCC8);
No administration of any anti-NSCLC therapy in the pre-operative period;
Be able to undergo the radical resection; Pulmonary function capacity capable of tolerating the proposed lung resection according to the surgeon.
Histologically confirmed the presence of small cell lung cancer, neuroendocrine carcinoma, sarcoma, salivary gland tumor, and mesenchymal tumor components, or mixed NSCLC with predominant squamous cell carcinoma features;
Tumor invasion of surrounding important structures, which is symptomatic or medical intervention indicated;
Pancoast tumor;
Malignant tumor nodule in the contralateral lung lobe;